Background
Retrospective comparison of 3D-conformal RT (3D-CRT) versus intensity-modulated radiation therapy (IMRT) for esophageal cancer treatment outcomes and toxicity. 676 patients treated at MD Anderson Cancer Center between 1998 and 2011 were analyzed. The study assessed clinical outcomes and toxicities including cardiac, pulmonary, and esophageal endpoints comparing the two RT modalities.
Interventions and follow up
Arm A: IMRT (n=232)
Arm B: 3D-CRT (n=444)
Primary endpoint: Grade ≥3 treatment-related toxicity (cardiac, pulmonary)
mFollow up: Median 27.3 month
Arm B: 3D-CRT (n=444)
Primary endpoint: Grade ≥3 treatment-related toxicity (cardiac, pulmonary)
mFollow up: Median 27.3 month
Results
Grade ≥3 pericardial effusion: 2.1% (IMRT) vs 4.3% (3D-CRT), P=.007
Grade ≥3 radiation pneumonitis: 0.4% (IMRT) vs 3.6% (3D-CRT), P=.003
2-year OS: 36% (IMRT) vs 38% (3D-CRT) — not significantly different
Locoregional recurrence: Similar between arms
Grade ≥3 radiation pneumonitis: 0.4% (IMRT) vs 3.6% (3D-CRT), P=.003
2-year OS: 36% (IMRT) vs 38% (3D-CRT) — not significantly different
Locoregional recurrence: Similar between arms
Adverse events
Main adverse events: IMRT was associated with significantly lower rates of grade 3+ cardiac (pericardial effusion) and pulmonary (radiation pneumonitis) toxicity compared to 3D-CRT, without compromising local control or overall survival. Esophageal toxicity rates were similar.
Conclusions
IMRT for esophageal cancer significantly reduces severe cardiac and pulmonary toxicities compared to 3D-CRT while maintaining equivalent oncologic outcomes. IMRT allows more conformal dose distribution, reducing dose to the heart and lungs — organs particularly at risk with thoracic esophageal RT. These data support IMRT as the preferred radiation technique for esophageal cancer.
Key Limitations
Key Limitations: Retrospective analysis — patients treated in different eras with potentially different patient selection, staging, and systemic therapy practices. IMRT patients were more recently treated and may benefit from improved systemic therapy independent of RT technique. The study was conducted at a single high-volume academic center; results may not apply to lower-volume institutions. Survival differences may be confounded by selection bias. IMRT plans were not systematically compared to optimized 3D-CRT plans.
Clinical Context
This study supported the rapid adoption of IMRT over 3D-CRT for esophageal cancer at most major centers. IMRT (or VMAT) is now the standard technique at high-volume centers given its ability to reduce heart and lung dose. NCCN guidelines recommend IMRT for esophageal cancer, particularly when lung V20 and mean heart dose reduction are clinically significant. Proton beam therapy (Lin JCO 2020) has further pushed dosimetric advantages but with higher cost and limited availability.
References